NDA 210922 · Alnylam Pharms INC
Onpattro
Patisiran Sodium · Intravenous
NovelBreakthrough therapyPriority reviewOrphanLast checked: Nov 19, 2026Latest source record: Jan 13, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Aug 10, 2018
Approved uses
2
Original approval plus efficacy supplements
Registered trials
11
5 Phase 3, 0 recruiting
FAERS reports
2,828
1,915 serious, 419 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 8, 2025.
ONPATTRO is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. ONPATTRO contains a transthyretin-directed small interfering RNA and is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
Mechanism: Patisiran is a double-stranded siRNA that causes degradation of mutant and wild-type TTR mRNA through RNA interference, which results in a reduction of serum TTR protein and TTR protein deposits in tissues.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 13, 2023 Supplement 12 · Efficacy OrphanLetterLabel
- Aug 10, 2018 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelLetterReview
1 products under this application
- ONPATTRO · PATISIRAN SODIUM EQ 10MG BASE/5ML (EQ 2MG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Patisiran" as an intervention, any sponsor and status, largest first.
- APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)Pivotal-lookingCompleted
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT03997383 · 360 participants · Start Sep 4, 2019 · Primary completion Jun 20, 2022
Drug: Placebo; Patisiran · For: Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Sites: Los Angeles, California; Chicago, Illinois; Skokie, Illinois · 90 sites in all
- APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated AmyloidosisPivotal-lookingCompleted
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT01960348 · 225 participants · Start Nov 2013 · Primary completion Aug 2017
Drug: patisiran (ALN-TTR02); Sterile Normal Saline (0.9% NaCl) · For: TTR-mediated Amyloidosis; Amyloidosis, Hereditary; Amyloid Neuropathies, Familial and 3 more
Sites: La Mesa, California; Orange, California; Denver, Colorado · 52 sites in all
- The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran)Pivotal-lookingCompleted
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT02510261 · 211 participants · Start Jul 16, 2015 · Primary completion Nov 23, 2022
Drug: Patisiran · For: Amyloidosis
Sites: La Mesa, California; Aurora, Colorado; Jacksonville, Florida · 56 sites in all
- HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)Pivotal-lookingCompleted
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT03759379 · 164 participants · Start Feb 14, 2019 · Primary completion Nov 10, 2020
Drug: Patisiran; Vutrisiran · For: Amyloidosis, Hereditary; Transthyretin Amyloidosis
Sites: La Mesa, California; Aurora, Colorado; Jacksonville, Florida · 64 sites in all
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT01617967 · 29 participants · Start May 2012 · Primary completion Oct 2013
Drug: Patisiran · For: TTR-mediated Amyloidosis
Sites: Boston, Massachusetts; Rio de Janeiro, Brazil; Le Kremlin-Bicêtre, France · 10 sites in all
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT01961921 · 27 participants · Start Oct 2013 · Primary completion Jul 2016
Drug: ALN-TTR02 (patisiran) administered by intravenous (IV) infusion · For: TTR-mediated Amyloidosis
Sites: Boston, Massachusetts; Rio de Janeiro, Brazil; Le Kremlin-Bicêtre, France · 9 sites in all
- Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progression Post-Liver TransplantPivotal-lookingCompleted
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT03862807 · 24 participants · Start Mar 27, 2019 · Primary completion Oct 6, 2020
Drug: Patisiran · For: Amyloidosis, Familial; Transthyretin Amyloidosis
Sites: Créteil, France; Le Kremlin-Bicêtre, France; Münster, Germany · 9 sites in all
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT01559077 · 17 participants · Start Mar 2012 · Primary completion Jun 2012
Drug: ALN-TTR02; Sterile Normal Saline (0.9% NaCl) · For: TTR-mediated Amyloidosis
Sites: Leeds, United Kingdom; London, United Kingdom
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death270
- product dose omission issue179
- fatigue174
- hospitalisation132
- infusion related reaction129
- asthenia117
- fall116
- intentional dose omission115
- cardiac failure101
- dyspnoea94
- malaise89
- inappropriate schedule of product administration85
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2018 | 41 |
| 2019 | 514 |
| 2020 | 332 |
| 2021 | 484 |
| 2022 | 532 |
| 2023 | 413 |
| 2024 | 295 |
| 2025 | 145 |
| 2026 | 72 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Onpattro (Patisiran Sodium,Lipid Complex)
2024 spending
$7.0M
Beneficiaries
25
248 claims
Per beneficiary
$279,702
$1,972.51 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $5,565,175 |
| 2021 | $11,429,867 |
| 2022 | $16,396,639 |
| 2023 | $9,169,028 |
| 2024 | $6,992,561 |
Part B: Onpattro (Patisiran Sodium,lipid Complex) · HCPCS J0222
2024 spending
$24.0M
Beneficiaries
84
944 claims
Per beneficiary
$286,149
2024 ASP limit $99.35 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $60,532,022 |
| 2021 | $82,896,519 |
| 2022 | $98,102,746 |
| 2023 | $37,700,003 |
| 2024 | $24,036,500 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis.
Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. · N Engl J Med 2018 · Clinical Trial, Phase III, Multicenter Study
- Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial.
Adams D, Tournev IL, Taylor MS, et al. · Amyloid 2023 · Randomized Controlled Trial
- Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis.
Maurer MS, Kale P, Fontana M, et al. · N Engl J Med 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta-analysis.
Antonopoulos AS, Panagiotopoulos I, Kouroutzoglou A, et al. · Eur J Heart Fail 2022 · Meta-Analysis, Systematic Review
- RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges.
Yu AM, Choi YH, Tu MJ · Pharmacol Rev 2020 · Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation.
Schmidt HH, Wixner J, Planté-Bordeneuve V, et al. · Am J Transplant 2022 · Clinical Trial, Phase III, Research Support, Non-U.S. Gov't
Sponsor: Alnylam Pharmaceuticals
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.